EU-OPENSCREEN signs Memorandum of Understanding

23 October 2017

The European infrastructure EU-OPENSCREEN and the European Lead Factory executives of the European Screening Centre and the Public Chemistry Consortium have signed a Memorandum of Understanding for collaboration in future initiatives.

The two consortia have a common deep interest in the discovery and development of small molecule compounds that specifically modulate the biological function of target proteins and recognize that they represent complementary initiatives which serve the needs of basic, applied and pharmaceutically directed research. Therefore, the partners consider the exploitation of synergistic potential and complementarity between their activities mutually attractive.

Phil Gribbon, coordinator of EU-OPENSCREEN is very pleased with this Memorandum: ‘At a practical level, this could lead to collaboration in which we are better able to serve the needs of users. It gives users improved access, via local organisations, to the excellent complementary facilities for enabling drug discovery which are available at the European Lead Factory.’


EU-OPENSCREEN, the European Infrastructure of Open Screening Platforms for Chemical Biology, is part of the ESFRI Roadmap which lists important future research infrastructures in Europe. EU-OPENSCREEN aims to satisfy the needs for new bioactive compounds in all fields of the Life Sciences and will help to increase knowledge on the bioactivities of chemical substances as well as the responses of biological systems to challenge with these substances. EU-OPENSCREEN will involve Europe's leading academic compound screening sites. It is open to external users and will offer access to all technologies and resources required for cutting-edge research on the discovery of biologically active substances. Quality controlled data of high scientific value, as well as tool compounds to facilitate both basic and applied research projects will be made available to the public.